PharmaLectures.com

Courses › Pharma training by country › Same molecule, different rulebook: Korean regulation versus the EU

Same molecule, different rulebook: Korean regulation versus the EU

Your Korean team files once and Europe finds nothing to send back.

  • 8 audio modulesthree lengths each
  • 1 h 20 min to 6 h 40 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Korea companieswho it is written for

Why this training matters

Your dossier follows Korean habits, and the European Medicines Agency stops it at validation. Later the first batch sits unreleased at the importer because the Qualified Person cannot certify from the file you sent. The launch date moves and your European partner starts asking who owns this.

What changes after this course

Your team plans one filing that satisfies the Ministry of Food and Drug Safety and the European Medicines Agency, and sends batch papers a Qualified Person can sign. You hold a certificate for every learner and a training record for each person, ready for the next audit.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs team stops treating a Korean approval as a head start in Europe. They map the Pharmaceutical Affairs Act to Directive 2001/83/EC, name a European applicant under Article 8, settle the Paediatric Investigation Plan early, and build Module 1 through Module 5 of the Common Technical Document so validation finds less to question. They know what electronic Common Technical Document version 4.0 means for the next filing.

A European inspector asks how your plant prevents cross-contamination on shared lines, and your quality assurance manager points to the answer already written under EudraLex Volume 4, Chapter 5. Deviations follow one procedure that serves Chapter 1, the International Council for Harmonisation Q10 guideline and your Korean auditor. Batch records are written for the person who reads them cold.

Pharmacovigilance specialists send one serious case to EudraVigilance in the E2B(R3) format and to the Korean authorities from the same source record, before the clock runs out. Regulatory staff sort every site or specification change as Type IA, IB or II under Regulation (EC) No 1234/2008, and no one files a Korean change report and forgets the European variation. They also check the periodic safety update report dates Europe sets per substance.

Supply chain managers ship batch files the European importer can act on at once. The certificate of analysis, the manufacturing site's Good Manufacturing Practice status and the batch record extracts are ready for the Qualified Person's check under Annex 16, and the importer's testing on import under Article 51 of Directive 2001/83/EC starts without a request for more papers.

Who needs this training

  • Regulatory Affairs Manager

    Your Korean approval is in hand and the European filing is next. You need to decide who holds the licence, which Module 1 pages change and when the Paediatric Investigation Plan must be agreed.

  • Quality Assurance Manager

    A European inspector asks for your deviation procedure and your management review under Chapter 1. You hand over records that already answer both, instead of explaining Korean practice.

  • Pharmacovigilance Specialist

    A serious case arrives on a Thursday afternoon. You know which system gets it, in which format, and which dates apply in Europe and in Korea, without calling head office.

  • Supply Chain and Logistics Manager

    The first European batch is on its way. You send the certificate of analysis and batch papers the importer's Qualified Person needs under Annex 16, so release is not waiting on an email chain.

  • Regulatory Affairs Specialist for Variations

    A site change is approved internally on Monday. You decide the same day whether it is a Type IA, IB or II variation in Europe and whether Korea needs a report.

Roles: Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: Korea

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Match each article of the Pharmaceutical Affairs Act that matters to your product to its counterpart in Directive 2001/83/EC.
  2. Name the applicant and check the Paediatric Investigation Plan status before submitting a centralised marketing authorisation application.
  3. Answer an inspector's cross-contamination question for a shared line by pointing to the EudraLex Volume 4, Chapter 5 controls in your own records.
  4. Send a serious adverse event case to EudraVigilance in the E2B(R3) format and to the Korean authorities from one source record.
  5. Classify a manufacturing site or specification change as Type IA, IB or II under Commission Regulation (EC) No 1234/2008 and record the reason.
  6. Assemble a batch file that gives a Qualified Person what Annex 16 asks for before certification.
  7. Write a deviation procedure that meets EudraLex Volume 4, Chapter 1 and the International Council for Harmonisation Q10 guideline.

What the company gets

  • Your European application arrives with a named applicant, an agreed Paediatric Investigation Plan and a Common Technical Document that validation has little reason to question.
  • Your quality system answers the inspector's first questions from its own records, so an inspection of a shared line becomes a conversation, not a scramble.
  • Batch files reach the European importer complete, so the Qualified Person can certify under Annex 16 without chasing your plant for missing papers.
  • Serious cases reach EudraVigilance and the Korean authorities on time, and periodic safety update reports follow the dates Europe has set.
  • You hold a certificate for each learner and a training record per person, ready when an auditor or a partner asks who was trained.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 8 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 20 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard3 h 20 min25 min a module, for regulatory, quality and business-development staff
Expanded6 h 40 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Regulatory affairsStandard3 h 20 min
Quality assurance and Qualified PersonStandard3 h 20 min

Course outline: 8 modules

8 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Map the Pharmaceutical Affairs Act to Directive 2001/83/EC and spot the gaps

    • Why a Korean approval earns no shortcut in Europe, and what you tell the board instead.
    • The Article 8 rule in Directive 2001/83/EC that decides who may hold your European licence.
    • What to do when a Pharmaceutical Affairs Act term has no twin in Directive 2001/83/EC.
  2. 2File a new drug application that clears the European centralised procedure

    • How to settle the Paediatric Investigation Plan early, so validation does not stop your filing.
    • The Module 1 pages that differ by region, and why they cannot be copied from your Korean filing.
    • When to request eligibility for the centralised procedure and when the rule already decides for you.
  3. 3Align your plant with EudraLex Volume 4 and Korean manufacturing standards

    • The Chapter 5 cross-contamination question inspectors raise on shared lines, answered before they ask.
    • How to match each Korean manufacturing standard to its EudraLex Volume 4 chapter on a single sheet.
    • What to put in a batch record so an inspector reads it once and moves on.
  4. 4Report adverse events to EudraVigilance and Korean authorities on time

    • How to send one serious case to EudraVigilance and the Korean authorities from a single source record.
    • Why your pharmacovigilance Qualified Person must live in Europe, and who can fill that seat.
    • The periodic safety update report dates that Europe sets for you, not the ones you pick.
  5. 5Structure your Quality Management System to meet EudraLex Volume 4 Chapter 1

    • How to write one deviation procedure that satisfies Chapter 1 and your Korean auditor together.
    • What the management review under Chapter 1 must show, and the record that proves you did it.
    • The Chapter 7 contract points that make your outsourced laboratory hold up in a European inspection.
  6. 6File Type IA, IB and II variations without stopping supply

    • How to sort a change into Type IA, IB or II under Regulation (EC) No 1234/2008 at your desk.
    • When a change you report only in Korea still needs a European variation, and when it does not.
    • Why a Type IA change can be made first and notified after, and the conditions that must all be met.
  7. 7Send batch papers that clear customs and let a Qualified Person certify

    • What a Qualified Person checks under Annex 16 before signing, so your batch file already holds it.
    • Why the European importer's authorisation under Article 40 decides what your batch file must show.
    • Why your European importer retests each batch on import under Article 51, and how to prepare for it.
  8. 8Prepare digital filings for International Council for Harmonisation changes

    • What the electronic Common Technical Document version 4.0 changes for the files you send next.
    • Why the Q12 guideline's established conditions decide how much paperwork a later change needs.
    • How the E2B(R3) standard shapes the safety reports that EudraVigilance accepts from you.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

8 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 20 min in the briefing length and 6 h 40 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Korea companies. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 72 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team